文献速递血栓与止血MDS 与骨髓增殖性肿瘤

JAK2V617F相关骨髓增殖性肿瘤中的纤溶功能受损

Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms.
PubMed 文献 · J Thromb Haemost · 2024-09-12

研究比较Jak2V617F小鼠与野生型小鼠全血和血浆的tPA介导纤溶,并检测65例MPN患者(JAK2V617F 50例、CALR突变9例)与28例健康对照的血浆tPA clot lysis。结果显示Jak2V617F小鼠纤溶降低、纤溶酶生成减少,JAK2V617F和CALR患者 clot lysis time 延长,JAK2V617F患者PAI-1和α2-抗纤溶酶升高。

要点

  • Jak2V617F小鼠全血halo clot lysis rate低于Jak2WT(95±22 vs 147±39 AU/min,P<.05)。
  • JAK2V617F和CALR患者tPA相关纤溶受损,表现为clot lysis time延长。
  • JAK2V617F患者血浆PAI-1和α2-抗纤溶酶较对照显著升高。

核心结论

  • 结果提示tPA介导的纤溶受损是MPN患者重要的促血栓机制,需在更大规模研究中确认。

研究设计与样本

  • 研究评估造血限制性表达Jak2V617F小鼠与野生型(Jak2WT)小鼠全血和血浆的tPA介导纤溶,采用halo clot lysis、front lysis和纤溶酶生成试验。
  • 对65例MPN患者(JAK2V617F突变50例、CALR突变9例)与28例健康对照的血浆进行tPA clot lysis试验。

主要发现

  • Jak2V617F小鼠全血halo clot lysis rate显著低于Jak2WT(95±22 vs 147±39 AU/min,P<.05)。
  • Jak2V617F小鼠血浆halo clot lysis rate为130±27 vs Jak2WT 186±29 AU/min,front lysis rate为2.8±1.6 vs 6.1±1.2 μm.min-1(P<.05)。
  • Jak2V617F小鼠血浆凝块和标准化纤维蛋白凝块中纤溶酶生成均较Jak2WT小鼠显著减少。
  • JAK2V617F和CALR患者中观察到tPA相关纤溶受损伴clot lysis time延长。
  • JAK2V617F患者血浆PAI-1和α2-抗纤溶酶较对照显著升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需在更大规模研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myeloproliferative neoplasms (MPNs) are characterized by a high rate of thrombotic complications that contribute to morbidity and mortality. MPN-related thrombogenesis is assumed to be multifactorial, involving both procoagulant and proinflammatory processes. Whether impaired fibrinolysis also participates in the prothrombotic phenotype of MPN has been poorly investigated. OBJECTIVES: We determined whether MPN, particularly JAK2V617F-positive MPN, is associated with fibrinolytic changes. METHODS: Tissue-type plasminogen activator (tPA)-mediated fibrinolysis was evaluated both in whole blood and plasma from mice with a hematopoietic-restricted Jak2V617F expression compared with wild-type (WT) mice (Jak2WT) using (1) halo clot lysis, (2) front lysis, and (3) plasmin generation assays. tPA clot lysis assay was performed in the plasma from 65 MPN patients (JAK2V617F mutation, n = 50; CALR mutations, n = 9) compared with 28 healthy controls. RESULTS: In whole blood from Jak2V617F mice, we observed a decreased fibrinolysis characterized by a significantly lower halo clot lysis rate compared with Jak2WT (95 ± 22 vs 147 ± 39 AU/min; P < .05). Similar results were observed in plasma (halo clot lysis rate, 130 ± 27 vs 186 ± 29 AU/min; front lysis rate, 2.8 ± 1.6 vs 6.1 ± 1.2 μm.min-1; P < .05). Plasmin generation was significantly decreased both in plasma clots and standardized fibrin clots from Jak2V617F mice compared with Jak2WT mice. Among MPN patients, impaired tPA-related fibrinolysis with prolonged clot lysis time was observed in JAK2V617F and CALR patients. Plasminogen activator inhibitor-1 and α2-antiplasmin were significantly increased in plasma from JAK2V617F patients compared with controls. CONCLUSION: Our results suggest that impaired tPA-mediated fibrinolysis represents an important prothrombotic mechanism in MPN patients that requires confirmation in larger studies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bourrienne MC, Loyau S, Faille D, et al. Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms. J Thromb Haemost. 2024. PMID: 39260744. doi:10.1016/j.jtha.2024.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。